Maxigen Biotech Inc (TW:1783) — Market Cap & Net Worth
Market Cap & Net Worth: Maxigen Biotech Inc (1783)
Maxigen Biotech Inc (TW:1783) has a market capitalization of $108.92 Million (NT$3.46 Billion) as of June 18, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #18957 globally and #1059 in its home market, demonstrating a -1.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Maxigen Biotech Inc's stock price NT$38.55 by its total outstanding shares 89680000 (89.68 Million). Review 1783 total debt and obligations to assess the company's total debt and financial obligations.
Maxigen Biotech Inc Market Cap History: 2015 to 2026
Maxigen Biotech Inc's market capitalization history from 2015 to 2026. Data shows growth from $55.80 Million to $108.92 Million (5.14% CAGR).
Maxigen Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Maxigen Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
Maxigen Biotech Inc's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.46x
Maxigen Biotech Inc's market cap is 0.46 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $56.76 Million | $336.39 Million | -$12.25 Million | 0.17x | N/A |
| 2017 | $54.12 Million | $427.56 Million | $15.79 Million | 0.13x | 3.43x |
| 2018 | $55.72 Million | $427.68 Million | $57.05 Million | 0.13x | 0.98x |
| 2019 | $62.32 Million | $452.20 Million | $60.11 Million | 0.14x | 1.04x |
| 2020 | $58.16 Million | $457.69 Million | $63.31 Million | 0.13x | 0.92x |
| 2021 | $133.31 Million | $511.98 Million | $87.67 Million | 0.26x | 1.52x |
| 2022 | $134.63 Million | $604.43 Million | $139.40 Million | 0.22x | 0.97x |
| 2023 | $136.75 Million | $622.12 Million | $165.83 Million | 0.22x | 0.82x |
| 2024 | $138.30 Million | $680.65 Million | $190.17 Million | 0.20x | 0.73x |
| 2025 | $120.93 Million | $811.56 Million | $265.31 Million | 0.15x | 0.46x |
Competitor Companies of 1783 by Market Capitalization
Companies near Maxigen Biotech Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Maxigen Biotech Inc by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #164 globally with a market cap of $142.44 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #267 globally with a market cap of $94.60 Billion USD ( €80.92 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #340 globally with a market cap of $78.07 Billion USD ( €66.78 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #542 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #164 | Intuitive Surgical Inc | NASDAQ:ISRG | $142.44 Billion | $402.18 |
| #267 | EssilorLuxottica S. A. | PA:EL | $94.60 Billion | €174.75 |
| #340 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $78.07 Billion | €91.50 |
| #542 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Maxigen Biotech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Maxigen Biotech Inc's market cap moved from $55.80 Million to $ 108.92 Million, with a yearly change of 5.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$108.92 Million | -9.93% |
| 2025 | NT$120.93 Million | -12.56% |
| 2024 | NT$138.30 Million | +1.14% |
| 2023 | NT$136.75 Million | +1.57% |
| 2022 | NT$134.63 Million | +0.99% |
| 2021 | NT$133.31 Million | +129.21% |
| 2020 | NT$58.16 Million | -6.67% |
| 2019 | NT$62.32 Million | +11.84% |
| 2018 | NT$55.72 Million | +2.96% |
| 2017 | NT$54.12 Million | -4.64% |
| 2016 | NT$56.76 Million | +1.72% |
| 2015 | NT$55.80 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Maxigen Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.92 Million USD |
| MoneyControl | $108.92 Million USD |
| MarketWatch | $108.92 Million USD |
| marketcap.company | $108.92 Million USD |
| Reuters | $108.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more